Department of Health Promotion and Child Care, Internal Medicine and Medical Specialties, Università degli Studi di Palermo, Palermo, Italy.
Fondazione Istituto "G. Giglio" Cefalù, Palermo, Italy.
Clin Hemorheol Microcirc. 2022;82(1):37-51. doi: 10.3233/CH-221380.
In a cohort of subjects with asymptomatic carotid atherosclerosis (ACA), we have evaluated the neutrophil and lymphocyte count and their ratio (NLR), the gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2). At baseline, no difference was observed between ACA subjects and subject control group regarding neutrophil and lymphocyte count while was evident in ACA subjects a significant increase in MMP-2, MMP-9 and TIMP-2 associated to a significant decrease in TIMP-1. Dividing the ACA according to the number of cardiovascular risk factors (CRFs) we have observed an increase in lymphocyte count in the subgroup with 3-5 CRFs. Evaluating the leukocyte subtypes according to all the surrogate markers of insulin resistance has been noted, in the subgroups that exceed the medians of these markers, a significant increase in neutrophil and lymphocyte count without any variation of the NLR. Effecting the same evaluation for the MMP/TIMP pattern we observed, instead, that the same subgroups tend to show a decrease in MMP-2 and an increase in MMP-9. No difference instead for TIMP-1 and TIMP-2. The abnormality of the MMP/TIMP pattern, bearing in mind the cardiometabolic clustering present in this cohort of ACA subjects, would induce to use drugs able not only to cure the cardiometabolic risk factors but also to influence the MMP/TIMP profile.
在一组无症状颈动脉粥样硬化（ACA）患者中，我们评估了中性粒细胞和淋巴细胞计数及其比值（NLR）、明胶酶（MMP-2 和 MMP-9）及其组织抑制剂（TIMP-1 和 TIMP-2）。在基线时，ACA 患者和对照组在中性粒细胞和淋巴细胞计数方面没有差异，而在 ACA 患者中，MMP-2、MMP-9 和 TIMP-2 明显增加，同时 TIMP-1 明显减少。根据心血管危险因素（CRF）的数量将 ACA 分组后，我们观察到 3-5 个 CRF 亚组的淋巴细胞计数增加。根据所有胰岛素抵抗替代标志物评估白细胞亚型时，在这些标志物中位数以上的亚组中，中性粒细胞和淋巴细胞计数明显增加，而 NLR 没有任何变化。对于 MMP/TIMP 模式的相同评估，我们观察到相同的亚组倾向于显示 MMP-2 减少和 MMP-9 增加。TIMP-1 和 TIMP-2 则没有差异。鉴于该 ACA 患者队列中存在心脏代谢聚集，MMP/TIMP 模式的异常会促使使用不仅能治疗心脏代谢危险因素，而且能影响 MMP/TIMP 谱的药物。
